Astra-Oxford vaccine the escape route for many nations
Poorer countries are looking beyond Pfizer and Moderna to possibly more price-friendly options to combat Covid-19
22 November 2020 - 17:16
London — Trial successes from Pfizer and Moderna have buoyed hopes that a Covid-19 vaccine is coming soon. But much of the world, beyond rich nations such as the US, is counting on another company’s shot to escape the crisis.
Findings from the final stage of AstraZeneca’s vaccine studies are due to be released shortly, and the stakes for lower- and middle-income nations are immense. The shot developed with the University of Oxford accounts for more than 40% of the supplies going to those countries, based on deals tracked by London-based research firm Airfinity...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.